LEO Pharma appoints Paul Navarre new member of its Board of Directors
Paul Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies. From 2017-2020 he held the position as CEO of Ferring US Holding subsequent to ten years at Allergan, among other as President of International Operations (global except US) and President of EAME (Europe, Middle East and Africa). Prior to that, he spent 15 years at Procter & Gamble managing multiple countries and global brands in pharmaceuticals and Health and beauty care.
Paul Navarre has a solid track record of delivering sustainable top line growth and building high performance organizations in the specialty pharmaceutical business through scientific innovation and customer centric approaches.
“With his impressive career, Paul brings extensive strategic and commercial experience from the global biotech and dermatology market, that will be of great value to LEO Pharma in its ambitions to create future growth and become a top five company within medical dermatology. I am excited to be working together with Paul going forward”, said Jesper Brandgaard, chairman of the Board of Directors at LEO Pharma.
“It’s a privilege to join the Board of Directors at LEO Pharma at this time in the company’s history. With its ongoing transformation, many steps have already been taken to position the company for future growth and I look much forward to being part of continuing this development”, said Paul Navarre.
Paul Navarre was elected one of the Top 100 Most Inspiring People by PharmaVoice in 2019. In 2021 he completed the Insead Corporate Governance Course.
Contacts
Contact:
Henrik Heskjær
hdtdk@leo-pharma.com
+45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy9.7.2025 13:00:00 CEST | Pressemeddelelse
ADHAND is a phase 3b placebo-controlled clinical trial evaluating the efficacy and safety of tralokinumab in adult patients living with moderate-to-severe atopic dermatitis on the hands who are candidates for systemic therapy.1 The 16-week interim results of the ADHAND trial met the primary and all key secondary endpoints, showing statistically significant results compared to placebo. This analysis assessed outcomes up to Week 16, but the trial will continue through Week 32, with final results expected by the end of the year.
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)3.6.2025 09:00:00 CEST | Pressemeddelelse
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,(1,2) making it a potential therapeutic candidate for treating PPP.
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs2.6.2025 10:00:00 CEST | Pressemeddelelse
A few weeks ago, LEO Pharma announced the appointment of a new EVP for Global People & Corporate Affairs (GPCA) – Helle Hedegaard Juhl will be joining LEO Pharma on July 1. She joins LEO Pharma, alongside recently appointed EVP for International Operations Frederik Kier, to strengthen the company’s leadership and support the next phase of LEO Pharma's strategic journey and transformation
LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%15.5.2025 09:00:00 CEST | Pressemeddelelse
Three-month interim report (Q1) 2025 (Unaudited)
To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership13.5.2025 13:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 13 May 2025 -- At LEO Pharma, we have made significant progress on our transformation journey. With our strategy on the right track, we have reached a point on our journey that requires a focus on the long term and the profiles required to shape our future. In light of this, we are announcing the following changes to our Executive Management team: We will split the current Product Strategy and International Operations into two functions, and with this EVP Becki Morison will be leaving LEO Pharma, effective end of June 2025. Frederik Kier has been appointed as EVP, International Operations and will start at LEO Pharma on June 1, 2025. Frederik joins LEO Pharma from a position as Senior Vice President, Global Obesity Unit at Novo Nordisk. Frederik’s long career at Novo Nordisk spans commercial roles, including international experience as SVP Region Northwest Europe, and SVP Region AAMEO (Africa, Asia, Middle East and Oceania). Lisa Elliott, currently Vice President, Gl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom